Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., … Appleman, L. J. (2023). 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 34, pp. S1576–S1576). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.10.390

Kelly, W. K., D. C. Danila, C. -. C. Lin, J. -. L. Lee, N. Matsubara, P. J. Ward, A. J. Armstrong, et al. “264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).” In Annals of Oncology, 34:S1576–S1576. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.10.390.

Kelly WK, Danila DC, Lin C-C, Lee J-L, Matsubara N, Ward PJ, et al. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2023. p. S1576–S1576.

Kelly, W. K., et al. “264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S1576–S1576. Crossref, doi:10.1016/j.annonc.2023.10.390.

Kelly WK, Danila DC, Lin C-C, Lee J-L, Matsubara N, Ward PJ, Armstrong AJ, Pook DW, Kim M, Dorff T, Fischer S, Lin Y-C, Horvath LG, Sumey C, Yang Z, Jurida G, Connarn J, Penny H, Stieglmaier J, Appleman LJ. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2023. p. S1576–S1576.